siltuximab
siltuximab: 6 clinical trials tracked.
siltuximab evidence translation
What we can confirm
6 tracked trials
What it means
What to watch
Prepared research question
What is verified about siltuximab, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence6 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (6)
A Phase 1 Open-label Study to Evaluate the Safety and Efficacy of MK-6255 Monotherapy in Advanced Solid Tumors
Primary endpoint: Number of Participants Who Experience a Dose-limiting Toxicity (DLT) as Assessed Using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE), Version 6.0
A Phase 2, Open-label, Multicenter Study to Determine the Safety, Tolerability, and Efficacy of MK-1045 in Participants With Hematologic Malignancies
Primary endpoint: Cohort A Part 1: Number of Participants Who Experience Dose-Limiting Toxicity (DLT)
A Phase 2/3, Randomized, Open-Label, Comparison Study of MK-1045 Versus Blinatumomab in Participants With Relapsed or Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)
Primary endpoint: Percentage of Participants with Complete Remission (CR) in Study Part 1 and Part 2
Pilot Safety-feasibility Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
Primary endpoint: Incidence of all-grade cytokine release syndrome
Phase II Randomized Trial of Population PK Dosed Melphalan With Interleukin-6 Blockade With Siltuximab Vesrus BSA Based Melphalan in Patients With Multiple Myeloma Over Age 60 Undergoing Autologous Stem Cell Transplantation
Primary endpoint: rate of stringent complete response (sCR)
Screening Trial for Pain Relief in Schwannomatosis (STARFISH)
Primary endpoint: Change in worst pain intensity for each drug sub-study